Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

Abstract

We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V 1a , V 1b and V 2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V 1b receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V 1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V 2 /V 1a antagonist, conivaptan and the V 2 antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V 1a , V 1b and V 2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 246

1. 1.

   Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G, Landgraf R, Neumann I. Peptide and Nonpeptide Agonists and Antagonists for the Vasopressin and Oxytocin V1a, V1b, V2 and OT Receptors: Research Tools and Potential Therapeutic Agents. 2008;473-512.

   Not in our library10.1016/s0079-6123(08)00437-8

2. 2.

   du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG. The synthesis of oxytocin. J Am Chem Soc. 1954;76:3115-3121.

   Not in our library

3. 3.

   du Vigneaud V, Gish DT, Katsoyannis PG. A synthetic preparation possessing biological properties associated with arginine-vasopressin. J Am Chem Soc. 1954;76:4751-4752.

   Not in our library

4. 4.

   Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85:2149-2154.

   Not in our library

5. 5.

   Manning M. Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: a historical perspective. Biopolymers. 2008;90:203-212.

   Not in our library10.1002/bip.20802

6. 6.

   Sawyer WH, Manning M. Synthetic analogues of oxytocin and vasopressin. Annual Rev Pharmacol. 1973;13:5-17.

   Not in our library10.1146/annurev.pa.13.040173.000253

7. 7.

   Manning M, Grzonka Z, Sawyer WH, Beardwell C, Robertson G. Synthesis of posterior pituitary hormones and hormone analogues. The Pituitary. 1981;265-296.

   Not in our library

8. 8.

   Sawyer WH, Grzonka Z, Manning M. Neurohypophyseal peptides: design of tissue-specific agonists and antagonists. Mol Cell Endocrinol. 1981;22:117-134.

   Not in our library10.1016/0303-7207(81)90086-1

9. 9.

   Manning M, Sawyer WH, Schrier R. Development of Selective Agonists and Antagonists of Vasopressin and Oxytocin, Vasopressin. 1985;131-144.

   Not in our library

10. 10.

    Manning M, Bankowski K, Sawyer WH, Gash DM, Boer GJ. Selective agonists and antagonists of vasopressin. Vasopressin: Principles and Properties. 1987;335-368.

    Not in our library

11. 11.

    Manning M, Sawyer WH. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med. 1989;114:617-632.

    Not in our library

12. 12.

    Barberis C, Morin D, Durroux T, Mouillac B, Guillon G, Hibert M, Tribollet E, Manning M. Molecular pharmacology of vasopressin and oxytocin receptors and therapeutic potential. Manning. Drug News Perspect. 1999;12:279-292.

    Not in our library

13. 13.

    Manning M, Sawyer WH. Design, synthesis and some uses of receptor specific agonists and antagonists of vasopressin and oxytocin. J Receptor Res. 1993;13:195-214.

    Not in our library10.3109/10799899309073655

14. 14.

    Manning M, Sawyer WH, Jard S, Jamison R. Antagonists of vasopressin and oxytocin: current status and future perspectives. Vasopressin. 1991;297-309.

    Not in our library

15. 15.

    Chan WY, Wo NC, Stoev S, Cheng LL, Manning M. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays. Exp Physiol. 2000;85(Suppl):7S-18S.

    Not in our library10.1111/j.1469-445x.2000.tb00003.x

16. 16.

    Manning M, Flegel M, Fritkin M, Gilon C, Slaninova S. Neurohypophyseal peptide agonists and antagonists: a five decade trail from du Vigneaud to 2004. Peptides 2004. 2005;101-106.

    Not in our library

17. 17.

    Berde B, Boissonnas RA, Berde B. Basic pharmacological properties of synthetic analogues and homologues of the neurohypophysial hormones. Neurohypophysial Hormones and Similar Polypeptides, Handbook of Experimental Pharmacology 23. 1968;802-870.

    Not in our library

18. 18.

    Lebl M, Jost K, Lebl M, Brtnik F. Analogs with inhibitory properties. Handbook of Neurohypophyseal Hormone Analogs. 1988;2:17-72.

    Not in our library

19. 19.

    Pierzynski P. Oxytocin and vasopressin V1a receptors as new therapeutic targets in assisted reproduction. Reprod Biomed Online. 2011;22:9-16.

    Not in our library10.1016/j.rbmo.2010.09.015

20. 20.

    Hruby VJ, Smith CW, Udenfriend S, Meienhofer J. Structure-activity relationships of neurohypophyseal peptides. The Peptides: Analysis, Synthesis, Biology. 1987;77-207.

    Not in our library

21. 21.

    Frank E, Landgraf R. The vasopressin system – from antidiuresis to psychopathology. Eur J Pharmacol. 2008;583:226-242.

    Not in our library10.1016/j.ejphar.2007.11.063

22. 22.

    Jard S, Zingg HH, Bourque CW, Bichet DG. Vasopressin receptors. A historical survey. Adv Exp Med Biol. 1998;1-13.

    Not in our library

23. 23.

    Gimpl G, Fahrenholz F. The oxytocin receptor system: structure function and regulation. Physiol Rev. 2001;81:629-683.

    Not in our library10.1152/physrev.2001.81.2.629

24. 24.

    Insel TR, Young LJ. The neurobiology of attachment. Nat Rev Neurosci. 2001;2:129-136.

    Not in our library10.1038/35053579

25. 25.

    Bosch OJ, Meddle SL, Beiderbeck DI, Douglas AJ, Neumann ID. Brain oxytocin correlates with maternal aggression: link to anxiety. J Neurosci. 2005;25:6807-6815.

    Not in our library10.1523/jneurosci.1342-05.2005

26. 26.

    Huber D, Veinante P, Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science. 2005;308:245-248.

    Not in our library10.1126/science.1105636

27. 27.

    Ma S, Shipston MJ, Morilak D, Russell JA. Reduced hypothalamic vasopressin secretion underlies attenuated adrenocorticotropin stress responses in pregnant rats. Endocrinology. 2005;146:1626-1637.

    Not in our library10.1210/en.2004-1368

28. 28.

    Parker KJ, Buckmaster CL, Schatzberg AF, Lyons DM. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology. 2005;30:924-929.

    Not in our library10.1016/j.psyneuen.2005.04.002

29. 29.

    Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci. 2005;25:11489-11493.

    Not in our library10.1523/jneurosci.3984-05.2005

30. 30.

    Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S. Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2007;61:498-503.

    Not in our library10.1016/j.biopsych.2006.05.030

31. 31.

    Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology. 2003;28:193-198.

    Not in our library10.1038/sj.npp.1300021

32. 32.

    Harony H, Wagner S. The contribution of oxytocin and vasopressin to mammalian social behavior: potential role in autism spectrum disorder. Neurosignals. 2010;18:82-97.

    Not in our library10.1159/000321035

33. 33.

    Meyer-Lindenberg A, Domes G, Kirsch P, Heinrich M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci. 2011;12:524-538.

    Not in our library10.1038/nrn3044

34. 34.

    Striepens N, Kendrick KM, Maier W, Hurlemann R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front Neuroendocrinol. 2011;32:426-450.

    Not in our library10.1016/j.yfrne.2011.07.001

35. 35.

    Ellenbogen MA, Linnen AM, Grumet R, Cardoso C, Joober R. The acute effects of intranasal oxytocin on automatic and effortful attentional shifting to emotional faces. Psychophysiology. 2012;49:128-137.

    Not in our library10.1111/j.1469-8986.2011.01278.x

36. 36.

    Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr Pharm Des. 2005;11:205-225.

    Not in our library10.2174/1381612053382241

37. 37.

    Grazzini E, Lodboerer AM, Perrez-Martin A, Joubert D, Guillon G. Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla. Endocrinology. 1996;137:3906-3914.

    Not in our library10.1210/endo.137.9.8756565

38. 38.

    Wisniewski K, Galyean R, Schteingart CD, Tariga H, Croston G, Alagarsamy S, Riviere PJM, Lebl M, Meldal M, Knud J, Jensen KJ, Høeg-Jensen T. Synthesis and in vitro characterization of new potent and selective oxytocin receptor agonist. Peptides 2010. 2010;306-307.

    Not in our library

39. 39.

    Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, Tariga H, Alagarsamy S, Ly B, Dykert J, Qi S, Wisniewski K, Galyean R, Croston G, Schteingart CD, Rivière PJ. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension. J Pharmacol Exp Ther. 2011;337:786-796.

    Not in our library10.1124/jpet.111.178848

40. 40.

    Kwiatkowska A, Sobolewski D, Prahl A, Borovicková L, Slaninová J, Lammek B. Arginine vasopressin and its analogues-the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists. Eur J Med Chem. 2009;44:2862-2867.

    Not in our library10.1016/j.ejmech.2008.12.010

41. 41.

    Magafa V, Borovicková L, Slaninová J, Cordopatis P. Synthesis and biological activity of oxytocin analogues containing unnatural amino acids in position 9: structure activity study. Amino Acids. 2010;38:1549-1559.

    Not in our library10.1007/s00726-009-0372-2

42. 42.

    Muttenthaler M, Andersson A, de Araujo AD, Dekan Z, Lewis RJ, Alewood PF. Modulating oxytocin activity and plasma stability by disulfide bond engineering. J Med Chem. 2010;53:8585-8596.

    Not in our library10.1021/jm100989w

43. 43.

    Slusarz R, Slusarz MJ. An influence of the aromatic side chains conformations in positions 2 and 3 of vasopressin analogs on interactions with vasopressin and oxytocin receptors. QSAR Comb Sci. 2009;28:1166-1175.

    Not in our library

44. 44.

    Manning M, Stoev S, Bankowski K, Lebl M, Meldal M, Jensen KJ, Hoeg-Jensen T. Peptides versus nonpeptides as therapeutics: an exiting challenge for Big Pharma. Peptides 2010. 2010;366-367.

    Not in our library

45. 45.

    Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.

    Not in our library10.1016/s0079-6123(02)39017-4

46. 46.

    Freidinger RM, Pettibone DJ. Small molecule ligands for oxytocin and vasopressin receptors. Med Res Rev. 1997;17:1-16.

    Not in our library10.1002/(sici)1098-1128(199701)17:1<1::aid-med1>3.0.co;2-5

47. 47.

    Corbani M, Trueba M, Stoev S, Murat B, Mion J, Boulay V, Manning M, Guillon G. Design, synthesis and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors. J Med Chem. 2011;54:2864-2877.

    Not in our library10.1021/jm1016208

48. 48.

    Albizu L, Cottet M, Kralikova M, Stoev S, Seyer R, Brabet I, Roux T, Bazin H, Bourrier E, Lamarque L, Breton C, Rives ML, Newman A, Javitch J, Trinquet E, Manning M, Pin JP, Mouillac B, Durroux T. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat Chem Biol. 2010;6:587-594.

    Not in our library10.1038/nchembio.396

49. 49.

    Stewart JM, Young JD. Solid Phase Synthesis. 1984.

    Not in our library

50. 50.

    Holton PA. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br J Pharmacol. 1948;3:328-334.

    Not in our library10.1111/j.1476-5381.1948.tb00396.x

51. 51.

    Schild HO. pA, a new scale of the measurement of drug antagonism. Br J Pharmacol Chemother. 1947;2:189-206.

    Not in our library10.1111/j.1476-5381.1947.tb00336.x

52. 52.

    Dyckes DF, Nestor JJ, Ferger MF, du Vigneaud V. [1-β-mercapto-β,β-diethylpropionic acid]-8-lysine vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocin. J Med Chem. 1974;17:250-252.

    Not in our library10.1021/jm00248a028

53. 53.

    Munsick RA. Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology. 1960;66:451-457.

    Not in our library10.1210/endo-66-3-451

54. 54.

    Chan WY, Kelly N. A pharmacological analysis on the significance of the chemical functional groups of oxytocin to its oxytocic activity and on the effect of magnesium on the in vitro and in vivo oxytocic activity of neurohypophysial hormones. J Pharmacol Exp Ther. 1967;156:150-158.

    Not in our library

55. 55.

    Dekanski J. The quantitative assay of vasopressin. Br J Pharmacol. 1952;7:567-572.

    Not in our library10.1111/j.1476-5381.1952.tb00723.x

56. 56.

    Sawyer WH. Biologic assays for oxytocin and vasopressin. Methods Med Res. 1961;9:210-219.

    Not in our library

57. 57.

    Morel A, O’Carroll AM, Brownstein MJ, Lolait SJ. Molecular cloning and expression of a rat V1a vasopressin receptor. Nature. 1992;356:523-526.

    Not in our library10.1038/356523a0

58. 58.

    Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem. 1994;269:3304-3310.

    Not in our library

59. 59.

    Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem. 1994;269:27088-27092.

    Not in our library

60. 60.

    De Keyzer Y, Auzan C, Lenne F, Beldjord C, Thibonnier M, Bertagna X, Clauser E. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett. 1994;356:215-220.

    Not in our library10.1016/0014-5793(94)01268-7

61. 61.

    Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 1992;357:333-335.

    Not in our library10.1038/357333a0

62. 62.

    Lolait SJ, O’Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature. 1992;357:336-339.

    Not in our library10.1038/357336a0

63. 63.

    Butlen D, Guillon G, Rajerison RM, Jard S, Sawyer WH, Manning M. Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: effects of highly potent analogues and competitive inhibitors. Mol Pharmacol. 1978;14:1006-1017.

    Not in our library

64. 64.

    Kirk CJ, Guillon G, Balestre MN, Jard S. Stimulation, by vasopressin and other agonists, of inositol-lipid breakdown and inositol phosphate accumulation in WRK1 cells. Biochem J. 1986;240:197-204.

    Not in our library10.1042/bj2400197

65. 65.

    Kimura T, Tanizawa O, Mori K, Brownstein M, Okayama H. Structure and expression of a human oxytocin receptor. Nature. 1992;356:526-529.

    Not in our library10.1038/356526a0

66. 66.

    Bone EA, Fretten P, Palmer S, Kirk CJ, Michell RH. Rapid accumulation of inositol phosphates in isolated rat superior cervical sympathetic ganglia exposed to V1-vasopressin and muscarinic cholinergic stimuli. Biochem J. 1984;221:803-811.

    Not in our library10.1042/bj2210803

67. 67.

    Salomon Y, Londos C, Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 1974;58:541-548.

    Not in our library10.1016/0003-2697(74)90222-x

68. 68.

    Andrés M, Trueba M, Guillon G. Pharmacological characterization of F-180: a selective human V1a vasopressin receptor agonist of high affinity. Br J Pharmacol. 2002;135:1828-1836.

    Not in our library10.1038/sj.bjp.0704634

69. 69.

    Derick S, Cheng LL, Voirol MJ, Stoev S, Giacomini M, Wo NC, Szeto HH, Ben Mimoun M, Andres M, Gaillard RC, Guillon G, Manning M. [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology. 2002;143:4655-4664.

    Not in our library10.1210/en.2002-220363

70. 70.

    Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M. Position 4 analogues of [deamino-Cys1]arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity. J Pept Sci. 2006;12:190-198.

    Not in our library10.1002/psc.710

71. 71.

    Cantau B, Keppens S, De Wulf H, Jard S. 3H)-vasopressin binding to isolated rat hepatocytes and liver membranes: regulation by GTP and relation to glycogen phosphorylase activation. J Recept Res. 1980;1:137-168.

    Not in our library10.3109/10799898009044096

72. 72.

    Cheng LL, Stoev S, Manning M, Derick S, Pena A, Ben Mimoun M, Guillon G. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of deamino-[Cys1]arginine vasopressin at position 4. J Med Chem. 2004;47:2375-2388.

    Not in our library10.1021/jm030611c

73. 73.

    Pena A, Murat B, Trueba M, Ventura MA, Bertrand G, Cheng LL, Stoev S, Szeto HH, Wo NC, Brossard G, Serradeil-Le Gal C, Manning M, Guillon G. Pharmacological and physiological characterization of d[Leu4,Lys8]Vasopressin, the first V1b selective agonist for rat vasopressin/oxytocin receptors. Endocrinology. 2007;148:4136-4146.

    Not in our library10.1210/en.2006-1633

74. 74.

    Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M. Design and synthesis of the first selective agonists for the rat vasopressin V1b receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8. J Med Chem. 2007;50:835-847.

    Not in our library10.1021/jm060928n

75. 75.

    Lowbridge J, Manning M, Haldar J, Sawyer WH. Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxyl[Thr4,Gly7]oxytocin), and [7-glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity. J Med Chem. 1977;20:120-123.

    Not in our library10.1021/jm00211a025

76. 76.

    Lee AG, Cool DR, Grunwald WC, Neal DE, Buckmaster CL, Cheng MY, Hyde SA, Lyons DM, Parker KJ. A novel form of oxytocin in New World monkeys. Biol Lett. 2011;7:584-587.

    Not in our library10.1098/rsbl.2011.0107

77. 77.

    Gutkowska J, Jankowski M. Oxytocin re-visited: its role in cardiovascular regulation. J Neuroendocrinol. 2011;24:599-608.

    Not in our library10.1111/j.1365-2826.2011.02235.x

78. 78.

    Danalache BA, Gutkowska J, Slusarz MJ, Berezowska I, Jankowski M. Oxytocin-Gly-Lys-Arg: a novel cardiomyogenic peptide. PLoS ONE. 2010;5:e13643.

    Not in our library10.1371/journal.pone.0013643

79. 79.

    Sawyer WH, Acosta M, Balaspiri L, Judd J, Manning M. Structural changes in the arginine vasopressin, molecule that enhance antidiuretic activity and specificity. Endocrinology. 1974;94:1106-1115.

    Not in our library10.1210/endo-94-4-1106

80. 80.

    Zaoral M, Kolc J, Sorm F. Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-γ-aminobutyrine-vasopressin. 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin. Coll Czech Chem Comm. 1967;32:1250-1257.

    Not in our library

81. 81.

    Huguenin RL. Synthèse de la Phe2-Orn8-ocytocine, deux analogues de la vasopressine douse d’une activité pressorique selective. Helv Chim Acta. 1964;47:1934-1941.

    Not in our library

82. 82.

    Aurell C-J, Bengtsson B, Ekholm K, Kasprzykowska R, Nilson A, Person R, Trojnar J, Abbe M, Melin P, Giralt E, Andreu D. Development of vasopressor specific analogues with prolonged effects. Peptides 1990. 1991;671-673.

    Not in our library

83. 83.

    Wisniewski K, Galyean R, Tariga H, Alagarsamy S, Croston G, Heitzmann J, Kohan A, Wisniewska H, Laporte R, Rivière PJ, Schteingart CD. New, potent, selective, and short-acting peptidic V1a receptor agonists. J Med Chem. 2011;54:4388-4398.

    Not in our library10.1021/jm200278m

84. 84.

    Manning M, Coy EJ, Sawyer WH, Acosta M. Solid-phase synthesis and some pharmacological properties of 4-threonine analogs of vasopressins and vasotocin and of arginine-vasopressin and arginine-vasotocin. J Med Chem. 1973;16:463-466.

    Not in our library10.1021/jm00263a009

85. 85.

    Boissonnas RA, Guttmann S. Synthese d’analogues de l’oxytocine et de la lysine-vasopressine contenant de la phenylalanine ou de la tyrosine en position 2 et 3. Helv Chim Acta. 1960;43:190-200.

    Not in our library

86. 86.

    Guillon G, Murat B, Pena A, Trueba M, Ventura MA, Wo NC, Szeto HH, Stoev S, Cheng LL, Manning M, Rolka K, Rekowski P, Silberring J. Selective agonists for human and rat vasopressin V1b receptors. Peptides 2006. 2007;742-743.

    Not in our library

87. 87.

    Dyckes DF, Ferger MF, du Vigneaud V. Synthesis and some of the pharmacological properties of (4-leucine)-8-lysine-vasopressin and (1-deamino,4-leucine)-8-lysine-vasopressin. J Med Chem. 1973;16:843-847.

    Not in our library10.1021/jm00265a022

88. 88.

    Saito M, Sugimoto T, Tahara A, Kawashima H. Molecular cloning and characterization of rat V1b vasopressin receptor: evidence for its expression in extra-pituitary tissues. Biochem Biophys Res Commun. 1995;26:751-757.

    Not in our library10.1006/bbrc.1995.2033

89. 89.

    Griffante C, Green A, Curcuruto O, Haslam CP, Dickinson BA, Arban R. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. Br J Pharmacol. 2005;146:744-751.

    Not in our library10.1038/sj.bjp.0706383

90. 90.

    Roper JA, O’Carroll A-M, Young WS, Lolait SJ. The vasopressin Avprib receptor: molecular and pharmacological studies. Stress. 2011;14:98-115.

    Not in our library10.3109/10253890.2010.512376

91. 91.

    Kruszynski M, Lammek B, Manning M, Seto J, Haldar J, Sawyer WH. [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid), 2-(O-methyl)tyrosine] arginine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin. J Med Chem. 1980;23:364-368.

    Not in our library10.1021/jm00178a003

92. 92.

    Chan WY, Wo NC, Cheng LL, Manning M. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor. J Pharmacol Exp Ther. 1996;227:999-1003.

    Not in our library

93. 93.

    Manning M, Przybylski JP, Olma A, Klis WA, Kruszynski M, Wo NC, Pelton GH, Sawyer WH. No requirement of cyclic conformation of antagonists in binding to vasopressin receptors. Nature. 1987;329:839-840.

    Not in our library10.1038/329839a0

94. 94.

    Manning M, Nawrocka E, Misicka A, Olma A, Klis WA, Seto J, Sawyer WH. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-β,β-pentamethylenepropionic acid),2-D-isoleucine,4-valine]arginine-vasopressin at position 4. J Med Chem. 1984;27:423-429.

    Not in our library10.1021/jm00370a002

95. 95.

    Manning M, Klis WA, Kruszynski M, Przybylski JP, Olma A, Wo NC, Pelton GH, Sawyer WH. Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin. Int J Pept Protein Res. 1988;32:455-467.

    Not in our library10.1111/j.1399-3011.1988.tb01376.x

96. 96.

    Manning M, Bankowski K, Barberis C, Jard S, Elands J, Chan WY. Novel approach to the design of synthetic radioiodinated linear V1a receptor antagonists of vasopressin. Int J Pept Protein Res. 1992;40:261-267.

    Not in our library10.1111/j.1399-3011.1992.tb00300.x

97. 97.

    Barberis C, Balestre MN, Jard S, Tribollet E, Arsenijevic Y, Dreifuss JJ, Bankowski K, Manning M, Chan WY, Schlosser Y, Holsboer F, Elands Y. Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors. Neuroendocrinology. 1995;62:135-146.

    Not in our library10.1159/000126998

98. 98.

    Manning M, Olma A, Klis WA, Kolodziejczyk AM, Seto J, Sawyer WH. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin. J Med Chem. 1982;25:45-50.

    Not in our library10.1021/jm00343a009

99. 99.

    Manning M, Misicka A, Olma A, Klis WA, Bankowski K, Nawrocka E, Kruszynski M, Kolodziejczyk A, Cheng LL, Seto J, Wo NC, Sawyer WH. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors. J Med Chem. 1987;30:2245-2252.

    Not in our library10.1021/jm00395a012

100. 100.

     Sawyer WH, Bankowski K, Misicka A, Nawrocka E, Kruszynski M, Stoev S, Klis WA, Przybylski JP, Manning M. Potent V2 vasopressin antagonists with structural changes at their C-terminals. Peptides. 1988;9:157-163.

     Not in our library10.1016/0196-9781(88)90022-8

101. 101.

     Manning M, Przybylski J, Grzonka Z, Nawrocka E, Lammek B, Misicka A, Cheng LL, Chan WY, Wo NC, Sawyer WH. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids. J Med Chem. 1992;35:3895-3904.

     Not in our library10.1021/jm00099a018

102. 102.

     Akerlund M. Targeting the oxytocin receptor to relax the myometrium. Expert Opin Ther Targets. 2006;10:423-427.

     Not in our library10.1517/14728222.10.3.423

103. 103.

     Bankowski K, Manning M, Seto J, Haldar J, Sawyer WH. Design and synthesis of potent in vivo antagonists of oxytocin. Int J Pept Prot Res. 1980;16:382-391.

     Not in our library10.1111/j.1399-3011.1980.tb02962.x

104. 104.

     Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with atosiban. Int J Peptide Protein Res. 1995;46:244-252.

     Not in our library10.1111/j.1399-3011.1995.tb00596.x

105. 105.

     Elands J, Barberis C, Jard S, Tribollet E, Dreifuss J-J, Bankowski K, Manning M, Sawyer WH. 125I-labelled d(CH25[Tyr(Me)2,Thr4,Tyr-NH29]OVT: a selective oxytocin receptor ligand. Eur J Pharmacol. 1988;147:197-207.

     Not in our library10.1016/0014-2999(88)90778-9

106. 106.

     Melin P, Trojnar J, Johansson B, Vilhardt H, Akerlund M. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J Endocrinol. 1986;111:125-131.

     Not in our library10.1677/joe.0.1110125

107. 107.

     Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M, Yabuuchi Y. OPC-21268, as an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991;252:572-574.

     Not in our library10.1126/science.1850553

108. 108.

     Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867.

     Not in our library

109. 109.

     Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099-2112.

     Not in our library10.1056/nejmoa065181

110. 110.

     Tahara A, Tomura Y, Wade K-I, Kusayama T, Tsukada J, Takanashi M, Yatsu T, Uchida W, Tanaka A. A pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1997;282:301-308.

     Not in our library

111. 111.

     Ghali JK, Tam SW. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail. 2010;16:419-431.

     Not in our library10.1016/j.cardfail.2009.12.021

112. 112.

     Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol. 2011;7:151-161.

     Not in our library10.1038/nrendo.2010.229

113. 113.

     Gross PA, Wagner A, Decaux G. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. Kidney Int. 2011;80:594-600.

     Not in our library10.1038/ki.2011.78

114. 114.

     Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol. 2011;164:725-732.

     Not in our library10.1530/eje-10-1078

115. 115.

     Ferguson-Myrthil N. Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan. Cardiol Rev. 2010;18:313-321.

     Not in our library10.1097/crd.0b013e3181f5b3b7

116. 116.

     Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest. 1993;92:224-231.

     Not in our library10.1172/jci116554

117. 117.

     Manaenko A, Fathali N, Khatibi NH, Lekic T, Hasegawa Y, Martin R, Tang J, Zhang JH. Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury. Neurochem Int. 2011;58:542-548.

     Not in our library10.1016/j.neuint.2011.01.018

118. 118.

     Russell R, Doyle R, Turner J, Attkins N, Ramsey S, Weibley L, Bateman L, Bictash M, Neal-Morgan S, Ivarsson M, Pullen N. In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1a) receptor antagonist 4-[4-(4-chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245). Eur J Pharmacol. 2011;670:347-355.

     Not in our library10.1016/j.ejphar.2011.09.034

119. 119.

     Schönberger M, Leggett C, Kim SW, Hooker JM. Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography. Bioorg Med Chem Lett. 2010;20:3103-3106.

     Not in our library10.1016/j.bmcl.2010.03.108

120. 120.

     Litvin Y, Murakami G, Pfaff DW. Effects of chronic social defeat on behavioral and neural correlates of sociality: vasopressin, oxytocin and the vasopressinergic V1b receptor. Physiol Behav. 2011;103:393-403.

     Not in our library10.1016/j.physbeh.2011.03.007

121. 121.

     Zmily HD, Daifallah S, Ghali JK. Tolvaptan, hyponatremia, and heart failure. Int J Nephrol Renovasc Dis. 2011;4:57-71.

     Not in our library10.2147/ijnrd.s7032

122. 122.

     Pang PS, Gheorghiade M, Dihu J, Swedberg K, Khan S, Maggioni AP, Grinfeld L, Zannad F, Burnett JC, Ouyang J, Udelson JE, Konstam MA. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. Am Heart J. 2011;161:1067-1072.

     Not in our library10.1016/j.ahj.2011.02.027

123. 123.

     Gassanov N, Semmo N, Semmo M, Nia AM, Fuhr U, Er F. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol. 2011;67:333-346.

     Not in our library10.1007/s00228-011-1006-7

124. 124.

     Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le Fur G. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest. 1996;98:2729-2738.

     Not in our library10.1172/jci119098

125. 125.

     Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol. 2010;77:836-845.

     Not in our library10.1124/mol.109.061804

126. 126.

     Ranadive SA, Ersoy B, Favre H, Cheung CC, Rosenthal SM, Miller WL, Vaisse C. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin Endocrinol (Oxf). 2009;71:388-393.

     Not in our library10.1111/j.1365-2265.2008.03513.x

127. 127.

     Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992;105:787-791.

     Not in our library10.1111/j.1476-5381.1992.tb09058.x

128. 128.

     Naidech AM, Paparello J, Liebling SM, Bassin SL, Levasseur K, Alberts MJ, Bernstein RA, Muro K. Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients. Neurocrit Care. 2010;13:57-61.

     Not in our library10.1007/s12028-010-9379-5

129. 129.

     Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant. 2010;25:1524-1531.

     Not in our library10.1093/ndt/gfp731

130. 130.

     Williams PD, Clineschmidt BV, Erb JM, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Pettibone DJ, Reiss DR, Veber DF, Woyden CY. 1-(1-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl)-4H-3,1-benzoxazin-2(1H)-one (L-371-257): a new, orally bioavailable, non-peptide oxytocin antagonist. J Med Chem. 1995;38:4634-4636.

     Not in our library10.1021/jm00023a002

131. 131.

     Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, Schechter LE, Rizzo S, Rahman Z, Rosenzweig-Lipson S. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology. 2006;185:218-225.

     Not in our library10.1007/s00213-005-0293-z

132. 132.

     Liddle J, Allen MJ, Borthwick AD, Brooks DP, Davies DE, Edwards RM, Exall AM, Hamlett C, Irving WR, Mason AM, McCafferty GP, Nerozzi F, Peace S, Philp J, Pollard D, Pullen MA, Shabbir SS, Sollis SL, Westfall TD, Woollard PM, Wu C, Hickey DM. The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008;18:90-94.

     Not in our library10.1016/j.bmcl.2007.11.008

133. 133.

     Borthwick AD. Oral oxytocin antagonists. J Med Chem. 2010;53:6525-6538.

     Not in our library10.1021/jm901812z

134. 134.

     Wootten DL, Simms J, Massoura AJ, Trim JE, Wheatley M. Agonist-specific requirement for a glutamate in transmembrane helix 1 of the oxytocin receptor. Mol Cell Endocrinol. 2011;333:20-27.

     Not in our library10.1016/j.mce.2010.11.029

135. 135.

     Smith AS, Agmo A, Birnie AK, French JA. Manipulation of the oxytocin system alters social behavior and attraction in pair-bonding primates, Callithrix penicillata. Horm Behav. 2010;57:255-262.

     Not in our library10.1016/j.yhbeh.2009.12.004

136. 136.

     Olszewski PK, Klockars A, Olszewska AM, Fredriksson R, Schiöth HB, Levine AS. Molecular, immunohistochemical, and pharmacological evidence of oxytocin’s role as inhibitor of carbohydrate but not fat intake. Endocrinology. 2010;151:4736-4744.

     Not in our library10.1210/en.2010-0151

137. 137.

     Frantz MC, Rodrigo J, Boudier L, Durroux T, Mouillac B, Hibert M. Subtlety of the structure–affinity and structure–efficacy relationships around a nonpeptide oxytocin receptor agonist. J Med Chem. 2010;53:1546-1562.

     Not in our library10.1021/jm901084f

138. 138.

     Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue SF, Marquis KL, Hughes ZA, Rosenzweig-Lipson S. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology. 2010;58:69-77.

     Not in our library10.1016/j.neuropharm.2009.07.016

139. 139.

     Insel TR. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron. 2010;65:768-779.

     Not in our library10.1016/j.neuron.2010.03.005

140. 140.

     Rahman Z, Resnick L, Rosenzweig-Lipton SJ, Ring RH.

     Not in our library

141. 141.

     Beyer CE, Dwyer JM, Platt BJ, Neal S, Luo B, Ling HP, Lin Q, Mark RJ, Rosenzweig-Lipson S, Schechter LE. Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation. Psychopharmacology. 2010;209:303-311.

     Not in our library10.1007/s00213-010-1791-1

142. 142.

     Jard S, Gaillard RC, Guillon G, Marie J, Schoenenberg P, Muller AF, Manning M, Sawyer WH. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol Pharmacol. 1986;30:171-177.

     Not in our library

143. 143.

     Pradelles P, Morgat JL, Fromageot P, Camier M, Bonne D, Cohen P, Bockaert J, Jard S. Tritium labelling of 8-lysine vasopressin and its purification by affinity chromatography on sepharose bound neurophysins. FEBS Lett. 1972;26:189-192.

     Not in our library10.1016/0014-5793(72)80570-2

144. 144.

     Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature. 1984;312:315-321.

     Not in our library10.1038/312315a0

145. 145.

     Bockaert J, Roy C, Rajerison R, Jard S. Specific binding of (3H)lysine-vasopressin to pig kidney plasma membranes. Relationship of receptoroccupancy to adenylate cyclase activation. J Biol Chem. 1973;248:5922-5931.

     Not in our library

146. 146.

     Terillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V1a receptors. J Med Chem. 2002;45:2579-2588.

     Not in our library10.1021/jm010526+

147. 147.

     Serradeil-Le Gal C, Raufaste D, Derick S, Blankenstein J, Allen J, Pouzet B, Pascal M, Wagnon J, Ventura MA. Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand. Am J Physiol Regul Integr Comp Physiol. 2007;293:R938-R949.

     Not in our library10.1152/ajpregu.00062.2007

148. 148.

     Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN, Mattera R. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997;138:4109-4122.

     Not in our library10.1210/endo.138.10.5432

149. 149.

     Mouillac B, Chini B, Balestre MN, Elands J, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Jard S, Barberis C. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J Biol Chem. 1995;270:25771-25777.

     Not in our library10.1074/jbc.270.43.25771

150. 150.

     Oshikawa S, Tanoue A, Koshimizu TA, Kitagawa Y, Tsujimoto G. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Mol Pharmacol. 2004;65:623-629.

     Not in our library10.1124/mol.65.3.623

151. 151.

     Chini B, Mouillac B, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Andriolo M, Pupier S, Jard S, Barberis C. Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett. 1996;397:201-206.

     Not in our library10.1016/s0014-5793(96)01135-0

152. 152.

     Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998;125:1463-1470.

     Not in our library10.1038/sj.bjp.0702220

153. 153.

     Elands J, Barberis C, Jard S. [3H]-[Thr4,Gly7]OT: a highly selective ligand for central and peripheral OT receptors. Am J Physiol. 1988;254:E31-E38.

     Not in our library10.1152/ajpendo.1988.254.1.e31

154. 154.

     Chini B, Mouillac B, Ala Y, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, Jard S. Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J. 1995;14:2176-2182.

     Not in our library10.1002/j.1460-2075.1995.tb07211.x

155. 155.

     Andrés M, Peña A, Derick S, Raufaste D, Trojnar J, Wisniewski K, Trueba M, Serradeil-Le Gal C, Guillon G. Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms. Eur J Pharmacol. 2004;501:59-69.

     Not in our library10.1016/j.ejphar.2004.08.026

156. 156.

     Chini B, Manning M. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. Biochem Soc Trans. 2007;35:737-741.

     Not in our library10.1042/bst0350737

157. 157.

     Chini B, Manning M, Guillon G. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an ‘easy guide’ to receptor pharmacology. Prog Brain Res. 2008;170:513-517.

     Not in our library10.1016/s0079-6123(08)00438-x

158. 158.

     Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V, Finardi A, Donzelli A, Pattini L, Rubino T, Parolaro D, Nishimori K, Parenti M, Chini B. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry. 2011;69:875-882.

     Not in our library10.1016/j.biopsych.2010.12.022

159. 159.

     Mimoun MB, Derick S, Andres M, Guillon G, Wo NC, Chan WY, Stoev S, Cheng LL, Manning M, Martinez J, Fehrentz JA. Vasopressin V2 agonists: affinities for human and rat V2 and V1a receptors reveal surprising species differences. Peptides 2000. 2001;589-590.

     Not in our library

160. 160.

     Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. J Pept Sci. 2005;11:593-608.

     Not in our library10.1002/psc.667

161. 161.

     Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, Bardou M, Martinolle JP, Pouzet B, Raufaste D, Garcia C, Double-Cazanave E, Pauly M, Pascal M, Barbier A, Scatton B, Maffrand JP, Le Fur G. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J Pharmacol Exp Ther. 2004;309:414-424.

     Not in our library10.1124/jpet.103.061200

162. 162.

     Schmidt A, Audigier S, Barberis C, Jard S, Manning M, Kolodziejczyk AS, Sawyer WH. A radioidinated linear vasopresin antagonist. FEBS. 1991;282:77-81.

     Not in our library10.1016/0014-5793(91)80448-c

163. 163.

     Jasper JR, Harrell CM, O’Brien JA, Pettibone DJ. Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57:2253-2261.

     Not in our library10.1016/0024-3205(95)02218-8

164. 164.

     Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther. 2002;300:1122-1130.

     Not in our library10.1124/jpet.300.3.1122

165. 165.

     Peters MF, Vaillancourt F, Heroux M, Valiquette M, Scott CW. Comparing label-free biosensors for pharmacological screening with cell-based functional assays. Assay Drug Dev Technol. 2010;8:219-227.

     Not in our library10.1089/adt.2009.0232

166. 166.

     Busnelli M, Sauliere A, Manning M, Bouvier M, Gales C, Chini B. Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem. 2012;287:3617-3629.

     Not in our library10.1074/jbc.m111.277178

167. 167.

     Caldwell HK, Lee H-J, Macbeth AH, Young WS. Vasopressin: behavioral roles of an original neuropeptide. Prog in Neurobiol. 2008;84:1-24.

     Not in our library10.1016/j.pneurobio.2007.10.007

168. 168.

     Kelly JM, Abrahams JM, Philips PA, Mendelsohn FA, Grzonka Z, Johnston CI. [125I]-[d(CH25,Sar7]AVP: a selective radioligand for V1 vasopressin receptors. J Recept Res. 1989;9:27-41.

     Not in our library10.3109/10799898909066043

169. 169.

     Tribollet E, Goumaz M, Raggenbass M, Dreifuss JJ. Appearance and transient expression of vasopressin and oxytocin receptors in the rat brain. J Recept Res. 1991;11:333-346.

     Not in our library10.3109/10799899109066412

170. 170.

     Hernando F, Schoots O, Lolait SJ, Burbach JPH. Immunohistochemical localisation of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology. 2001;142:1659-1668.

     Not in our library10.1210/endo.142.4.8067

171. 171.

     Hurbin A, Boissin-Agasse L, Orcel H, Rabié A, Joux N, Desarménien MG, Richard P, Moos FC. The V1a and V1b, but not V2, vasopressin receptor genes are expressed in the supraoptic nucleus of the rat hypothalamus, and the transcripts are essentially colocalized in the vasopressinergic magnocellular neurons. Endocrinology. 1998;139:4701-4707.

     Not in our library10.1210/endo.139.11.6320

172. 172.

     Hurbin A, Dubrez L, Coll JL, Favrot MC. The vasopressin receptors colocalize with vasopressin in the magnocellular neurons of the rat supraoptic nucleus and are modulated by water balance. Endocrinology. 2002;143:456-466.

     Not in our library10.1210/endo.143.2.8643

173. 173.

     Young WS, Li J, Wersinger SR, Palkovits M. The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience. 2006;143:1031-1039.

     Not in our library10.1016/j.neuroscience.2006.08.040

174. 174.

     Mouillac B, Manning M, Durroux T. Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies. Mini Rev Med Chem. 2008;8:996-1005.

     Not in our library10.2174/138955708785740607

175. 175.

     Taki M, Hohsaka T, Murakami H, Taira K, Sisido M. A non-natural amino acid for efficient incorporation into proteins as a sensitive fluorescent probe. FEBS Lett. 2001;507:35-38.

     Not in our library10.1016/s0014-5793(01)02935-0

176. 176.

     Panchuk-Voloshina N, Haugland RP, Bishop-Stewart J, Bhalgat MK, Millard PJ, Mao F, Leung W-Y, Huagland R. Alexa dyes, a series of new fluorescent dyes that yield exceptionally bright, photostable conjugates. J Histochem Cytochem. 1999;47:1179-1188.

     Not in our library10.1177/002215549904700910

177. 177.

     Ballard JL, Peeva VK, deSilva CJ, Lynch JL, Swanson NR. Comparison of Alexa Fluor and Cy Dye for practical DNA microarray use. Mol Biotechnol. 2007;36:175-183.

     Not in our library10.1007/s12033-007-0006-4

178. 178.

     Durroux T, Peter M, Turcatti G, Cholet A, Balestre MN, Barberis C, Seyer R. Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis and applications. J Med Chem. 2009;42:1312-1319.

     Not in our library10.1021/jm9804782

179. 179.

     Kirk KL, Buku A, Eggena P. Cell specificity of vasopressin binding in renal collecting duct: computer-enhanced imaging of a fluorescent hormone analog. Proc Natl Acad Sci USA. 1987;84:6000-6004.

     Not in our library10.1073/pnas.84.16.6000

180. 180.

     Bonnet D, Riché S, Loison S, Dagher R, Frantz MC, Boudier L, Rameh R, Mouillac B, Haiech J, Hibert M. Solid-phase organic tagging resins for labeling biomolecules by 1,3-dipolar cycloaddition: application to the synthesis of a fluorescent non-peptidic vasopressin recptor ligand. Chemistry. 2008;14:6247-6254.

     Not in our library10.1002/chem.200800273

181. 181.

     Maurel D, Kniazeff J, Mathis G, Trinquet E, Pin JP, Ansanay H. Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology. Anal Biochem. 2004;329:253-262.

     Not in our library10.1016/j.ab.2004.02.013

182. 182.

     Milligan G, Bouvier M. Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J. 2005;272:2914-2925.

     Not in our library10.1111/j.1742-4658.2005.04731.x

183. 183.

     Albizu L, Balestre MN, Breton C, Pin JP, Manning M, Mouillac B, Barberis C, Durroux T. Probing the existence of G protein-coupled recptor dimers by positive and negative ligand-dependent cooperative binding. Mol Pharmacol. 2006;70:1783-1791.

     Not in our library10.1124/mol.106.025684

184. 184.

     Orcel H, Albizu L, Perkovska S, Durroux T, Mendre C, Ansanay H, Mouillac B, Rabié A. Differential coupling of the vasopressin V1b receptor through compartmentalization within the plasma membrane. Mol Pharmacol. 2009;75:637-647.

     Not in our library10.1124/mol.108.049031

185. 185.

     Terrillon S, Durroux T, Mouillac B, Breit A, Ayoub MA, Taulan M, Jockers R, Barberis C, Bouvier M. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol. 2003;17:677-691.

     Not in our library10.1210/me.2002-0222

186. 186.

     Devost D, Zingg HH. Homo- and hetero-dimeric complex formations of the human oxytocin receptor. J Neuroendocrinol. 2004;16:372-377.

     Not in our library10.1111/j.0953-8194.2004.01188.x

187. 187.

     Pin JP, Maurel D, Comps-Agrar L, Monnier C, Rives A-L, Doumazane E, Rondard P, Durroux T, Prezeau L, Trinquet E, Siehler S, Milligan G. Time-resolved FRET approaches to study GPCRs complexes. G Protein-Coupled Receptors; Structure, Signaling and Physiology. 2011;67-90.

     Not in our library

188. 188.

     Albizu L, Teppaz G, Seyer R, Bazin H, Ansanay H, Manning M, Mouillac B, Durroux T. Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007;50:4976-4985.

     Not in our library10.1021/jm061404q

189. 189.

     Zwier JM, Roux T, Cottet M, Durroux T, Douzon S, Bdioui S, Gregor N, Bourrier E, Oueslati N, Nicolas L, Tinel N, Boisseau C, Yverneau P, Charrier-Savournin F, Fink M, Trinquet E. A fluorescent ligand-binding alternative using Tag-lite(R) Technology. J Biomol Screen. 2010;15:1248-1259.

     Not in our library10.1177/1087057110384611

190. 190.

     Cottet M, Faklaris O, Zwier JM, Trinquet E, Pin J-P, Durroux T. Original fluorescent ligand-based assays open new perspectives in G-protein coupled receptor drug screening. Pharmaceuticals. 2011;4:202-214.

     Not in our library

191. 191.
     Mechanisms of the Anti-Obesity Effects of Oxytocin in Diet-Induced Obese Rats · 2011

     No notice
192. 192.

     Sterns R, Hix J. Hyponatremia: vasopressin antagonists in hyponatremia: more data needed. Nat Rev Nephrol. 2011;7:132-133.

     Not in our library10.1038/nrneph.2010.173

193. 193.

     Vlieghe P, Lisowski V, Martinez J, Khrestchatisky JM. Synthetic therapeutic peptides: science and market. Drug Discovery Today. 2010;15:40-56.

     Not in our library10.1016/j.drudis.2009.10.009

194. 194.

     Reichert J. Development Trends for Peptide Therapeutics. 2010.

     Not in our library

195. 195.

     Assinder SJ. Oxytocin increases 5alpha-reductase activity of human prostate epithelial cells, but not stromal cells. Prostate. 2008;68:115-121.

     Not in our library10.1002/pros.20671

196. 196.

     Beery AK, Zucker I. Oxytocin and same-sex social behavior in female meadow voles. Neuroscience. 2010;169:665-673.

     Not in our library10.1016/j.neuroscience.2010.05.023

197. 197.

     Bosch OJ, Neumann ID. Both oxytocin and vasopressin are mediators of maternal care and aggression in rodents: from central release to sites of action. Horm Behav. 2011.

     Not in our library10.1016/j.yhbeh.2011.11.002

198. 198.

     Braida D, Donzelli A, Martucci R, Capurro V, Busnelli M, Chini B, Sala M. Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish. Psychopharmacology. 2012;220:319-330.

     Not in our library10.1007/s00213-011-2482-2

199. 199.
     Oxytocin-Induced Antinociception in the Spinal Cord is Mediated by a Subpopulation of Glutamatergic Neurons in Lamina I-II Which Amplify GABAergic Inhibition · 2008

     No notice
200. 200.

     Figueira RJ, Peabody MF, Lonstein JS. Oxytocin receptor activity in the ventrocaudal periaqueductal gray modulates anxiety-related behavior in postpartum rats. Behav Neurosci. 2008;122:618-628.

     Not in our library10.1037/0735-7044.122.3.618

201. 201.

     Gupta J, Russell R, Wayman C, Hurley D, Jackson V. Oxytocin-induced contractions within rat and rabbit ejaculatory tissues are mediated by vasopressin V1a receptors and not oxytocin receptors. Br J Pharmacol. 2008;155:118-126.

     Not in our library10.1038/bjp.2008.226

202. 202.

     Israel JM, Poulain DA, Oliet SH. Oxytocin-induced postinhibitory rebound firing facilitates bursting activity in oxytocin neurons. J Neurosci. 2008;28:385-394.

     Not in our library10.1523/jneurosci.5198-07.2008

203. 203.

     Karavashkina TA, Kutina AV, Shakhmatova EI, Natochin YV. Mechanism of 1-deamino-arginine vasotocin induced natriuresis in rats. Gen Comp Endocrinol. 2011;170:460-467.

     Not in our library10.1016/j.ygcen.2010.10.020

204. 204.

     Karelina K, Stuller KA, Jarrett B, Zhang N, Wells J, Norman GJ, Devries AC. Oxytocin mediates social neuroprotection after cerebral ischemia. Stroke. 2011;42:3606-3611.

     Not in our library10.1161/strokeaha.111.628008

205. 205.

     Kennett JE, Poletini MO, Fitch CA, Freeman ME. Antagonism of oxytocin prevents suckling- and estradiol-induced, but not progesterone-induced, secretion of prolactin. Endocrinology. 2009;150:2292-2299.

     Not in our library10.1210/en.2008-1611

206. 206.

     Kim JS, Kim WB, Kim YB, Lee Y, Kim YS, Shen FY, Lee SW, Park D, Choi HJ, Hur J, Park JJ, Han HC, Colwell CS, Cho YW, Kim YI. Chronic hyperosmotic stress converts GABAergic inhibition into excitation in vasopressin and oxytocin neuronsin the rat. J Neurosci. 2011;31:13312-13322.

     Not in our library10.1523/jneurosci.1440-11.2011

207. 207.

     Lee H-J, Macbeth AH, Pagani J, Young WS. Oxytocin: the great facilitator of life. Prog Neurobiol. 2009;88:127-151.

     Not in our library10.1016/j.pneurobio.2009.04.001

208. 208.

     Lukas M, Toth I, Reber SO, Slattery DA, Veenema AH, Neumann ID. The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neuropsychopharmacology. 2011;36:2159-2168.

     Not in our library10.1038/npp.2011.95

209. 209.

     Macciò A, Madeddu C, Chessa P, Panzone F, Lissoni P, Mantovani G. Oxytocin both increases proliferative response of peripheral blood lymphomonocytes to phytohemagglutinin and reverses immunosuppressive estrogen activity. In Vivo. 2010;24:157-163.

     Not in our library

210. 210.

     Mak P, Broussard C, Vacy K, Broadbear JH. Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat. J Psychopharmacol. 2011.

     Not in our library10.1177/0269881111416687

211. 211.

     Nakamura K, Fujiwara Y, Mizutani R, Sanbe A, Miyauchi N, Hiroyama M, Yamaguchi J, Yamashita T, Nakamura S, Mori T, Tsujimoto G, Tanoue A. Effects of vasopressin V1b receptor deficiency on adrenocorticotropin release from anterior pituitary cells in responce to oxytocin stimulation. Endocrinology. 2008;149:4883-4891.

     Not in our library10.1210/en.2007-1528

212. 212.

     Neumann ID, Veenema AH, Beiderbeck DI. Aggression and anxiety: social context and neurobiological links. Front Behav Neurosci. 2010;4:12-28.

     Not in our library10.3389/fnbeh.2010.00012

213. 213.

     Norman GJ, Karelina K, Morris JS, Zhang N, Cochran M, Courtney DeVries A. Social interaction prevents the development of depressive-like behavior postnerve injury in mice: a potential role for oxytocin. Psychosom Med. 2010;72:519-526.

     Not in our library10.1097/psy.0b013e3181de8678

214. 214.

     Northrop LE, Erskine MS. Selective oxytocin receptor activation in the ventrolateral portion of the ventromedial hypothalamus is required for mating-induced pseudopregnancy in the female rat. Endocrinology. 2008;149:836-842.

     Not in our library10.1210/en.2007-1040

215. 215.

     Nyuyki KD, Waldherr M, Baeuml S, Neumann ID. Yes, i am ready now: differential effects of paced versus unpaced mating on anxiety and central oxytocin release in female rats. PLoS ONE. 2011;6:e23599.

     Not in our library10.1371/journal.pone.0023599

216. 216.

     Oldfield RG, Hofmann HA. Neuropeptide regulation of social behavior in a monogamous cichlid fish. Physiol Behav. 2011;102:296-303.

     Not in our library10.1016/j.physbeh.2010.11.022

217. 217.

     Saito A, Nakamura K. Oxytocin changes primate paternal tolerance to offspring in food transfer. J Comp Physiol A Neuroethol Sens Neural Behav Physiol. 2011;197:329-337.

     Not in our library10.1007/s00359-010-0617-2

218. 218.

     Schorscher-Petcu A, Sotocinal S, Ciura S, Dupré A, Ritchie J, Sorge RE, Crawley JN, Hu SB, Nishimori K, Young LJ, Tribollet E, Quirion R, Mogil JS. Oxytocin-induced analgesia and scratching are mediated by the vasopressin-1A receptor in the mouse. J Neurosci. 2010;30:8274-8284.

     Not in our library10.1523/jneurosci.1594-10.2010

219. 219.

     Schorscher-Petcu A, Dupre A, Tribollet E. Distribution of vasopressin and oxytocin binding sites in the brain and upper spinal cord of the common marmoset. Neurosci Lett. 2009;461:217-222.

     Not in our library10.1016/j.neulet.2009.06.016

220. 220.

     Shirley DG, Walter MF, Keeler BD, Waters NJ, Walter SJ. Selective blockade of oxytocin and vasopressin V(1a) receptors in anaesthetised rats: evidence that activation of oxytocin receptors rather than V(1a) receptors increases sodium excretion. Nephron Physiol. 2011;117:21-26.

     Not in our library10.1159/000320290

221. 221.

     Slattery DA, Neumann ID. Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats. Neuropharmacology. 2010;58:56-61.

     Not in our library10.1016/j.neuropharm.2009.06.038

222. 222.

     Takada M, Fujimaki-Aoba K, Hokari S. Vasotocin- and mesotocin-induced increases in short-circuit current across tree frog skin. J Comp Physiol B. 2011;181:239-248.

     Not in our library10.1007/s00360-010-0523-5

223. 223.

     Teruyama R, Lipschitz DL, Wang L, Ramoz GR, Crowley WR, Bealer SL, Armstrong WE. Central blockade of oxytocin receptors during mid-late gestation reduces amplitude of slow afterhyperpolarization in supraoptic oxytocin neurons. Am J Physiol Endocrinol Metab. 2008;295:E1167-E1171.

     Not in our library10.1152/ajpendo.90620.2008

224. 224.

     Timmer M, Cordero MI, Sevelinges Y, Sandi C. Evidence for a role of oxytocin receptors in the long-term establishment of dominance hierarchies. Neuropsychopharmacology. 2011;36:2349-2356.

     Not in our library10.1038/npp.2011.125

225. 225.

     Veenema AH, Bredewold R, De Vries GJ. Vasopressin regulates social recognition in juvenile and adult rats of both sexes, but in sex- and age-specific ways. Horm Behav. 2012;61:50-56.

     Not in our library10.1016/j.yhbeh.2011.10.002

226. 226.

     Viero C, Shibuya I, Kitamura N, Verkhratsky A, Fujihara H, Katoh A, Ueta Y, Zingg HH, Chvatal A, Sykova E, Dayanithi G. REVIEW: Oxytocin: crossing the bridge between basic science and pharmacotherapy. CNS Neurosci Ther. 2010;16:e138-e156.

     Not in our library10.1111/j.1755-5949.2010.00185.x

227. 227.

     Viviani D, Charlet A, van den Burg E, Robinet C, Hurni N, Abatis M, Magara F, Stoop R. Oxytocin selectively gates fear responses through distinct outputs from the central amygdala. Science. 2011;333:104-107.

     Not in our library10.1126/science.1201043

228. 228.

     Vrachnis N, Malamas FM, Sifakis S, Deligeoroglou E, Iliodromiti Z. The oxytocin–oxytocin receptor system and its antagonists as tocolytic agents. Int J Endocrinol. 2011;2011:350546.

     Not in our library10.1155/2011/350546

229. 229.

     Waldherr M, Nyuyki K, Maloumby R, Bosch OJ, Neumann ID. Attenuation of the neuronal stress responsiveness and corticotrophin releasing hormone synthesis after sexual activity in male rats. Horm Behav. 2010;57:222-229.

     Not in our library10.1016/j.yhbeh.2009.11.006

230. 230.

     Wrobel LJ, Reymond-Marron I, Dupré A, Raggenbass M. Oxytocin and vasopressin enhance synaptic transmission in the hypoglossal motor nucleus of young rats by acting on distinct receptor types. Neuroscience. 2010;165:723-735.

     Not in our library10.1016/j.neuroscience.2009.11.001

231. 231.

     Yang J, Pan YJ, Zhao Y, Qiu PY, Lu L, Li P, Chen F, Yan XQ, Wang DX. Oxytocin in the rat caudate nucleus influences pain modulation. Peptides. 2011;32:2104-2107.

     Not in our library10.1016/j.peptides.2011.08.021

232. 232.

     Busnardo C, Tavares RF, Correa FM. Mechanisms involved in the pressor response to noradrenaline microinjection into the supraoptic nucleus of unanesthetized rats. Auton Neurosci. 2009;145:63-70.

     Not in our library10.1016/j.autneu.2008.11.005

233. 233.

     Chen J, Young S, Subburaju S, Sheppard AK, Atkinson H, Wood S, Lightman S, Serradeil-Le Gal C, Aguilera G. Vasopressin does not mediate hypersensivity of the hypothalamic pituitary adrenal axis during chronic stress. stress, neurotransmitters, and hormones. Ann NY Acad Sci. 2008;1148:349-359.

     Not in our library10.1196/annals.1410.037

234. 234.

     Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Dobruch J, Gomolka R, Puchalska L. Brain vasopressin V(1) receptors contribute to enhanced cardiovascular responses to acute stress in chronically stressed rats and rats with myocardial infarction. Am J Physiol Regul Integr Comp Physiol. 2010;298:R672-R680.

     Not in our library10.1152/ajpregu.00543.2009

235. 235.

     Dutertre S, Croker D, Daly NL, Andersson A, Muttenthaler M, Lumsden NG, Craik DJ, Alewood PF, Guillon G, Lewis RJ. Conopressin-T from Conus tulipa reveals an antagonist switch in vasopressin-like peptides. J Biol Chem. 2008;283:7100-7108.

     Not in our library10.1074/jbc.m706477200

236. 236.

     Goel M, Zuo CD, Schilling WP. Role of cAMP/PKA signalling cascade in vasopressin-induced trafficking of TRPC3 channels in principal cells of the collecting duct. Am J Physiol Renal Physiol. 2010;298:F988-F996.

     Not in our library10.1152/ajprenal.00586.2009

237. 237.

     Koshimizu TA, Tsujimoto G. New topics in vasopressin receptors and approach to novel drugs: vasopressin and pain perception. J Pharmacol Sci. 2009;109:33-37.

     Not in our library10.1254/jphs.08r18fm

238. 238.

     Kublaoui BM, Gemelli T, Tolson KP, Wang Y, Zinn AR. Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice. Mol Endocrinol. 2008;22:1723-1734.

     Not in our library10.1210/me.2008-0067

239. 239.

     Louiset E, Contesse V, Groussin L, Cartier D, Duparc C, Perraudin V, Bertherat J, Lefebvre H. Expression of vasopressin receptors in ACTH-independent macronodular bilateral adrenal hyperplasia causing Cushing’s syndrome: molecular, immunohistochemical and pharmacological correlates. J Endocrinol. 2008;196:1-9.

     Not in our library10.1677/joe-07-0413

240. 240.

     Rehberg S, Ertmer C, Lange M, Morelli A, Whorton E, Dunser M, Strohhacker AK, Lipke E, Kampmeier TG, Van Aken H, Traber DL, Westphal M. Role of selective V2-receptor-antagonism in septic shock: a randomized, controlled, experimental study. Crit Care. 2010;14:R200.

     Not in our library10.1186/cc9320

241. 241.

     Rodriguez-Borrero E, Rivera-Escalera F, Candelas F, Montalvo J, Munoz-Miranda WJ, Walker JR, Maldonado-Vlaar CS. Arginine vasopressin gene expression changes within the nucleus accumbens during environment elicited cocaine-conditioned response in rats. Neuropharmacology. 2010;58:88-101.

     Not in our library10.1016/j.neuropharm.2009.06.040

242. 242.

     Searcy BT, Bradford CS, Thompson RR, Fitz TM, Moore FL. Identification and characterization of mesotocin and V1a-like vasotocin receptors in a urodele amphibian, Taricha granulosa. Gen Comp Endocrinol. 2011;170:131-143.

     Not in our library10.1016/j.ygcen.2010.09.017

243. 243.

     Tanoue A. New topics in vasopressin receptors and approach to novel drugs: effects of vasopressin receptor on regulations of hormone secretion and metabolisms of glucose, fat, and protein. J Pharmacol Sci. 2009;109:50-52.

     Not in our library10.1254/jphs.08r15fm

244. 244.

     Veitenheimer B, Osborn JW. Role of spinal V1a receptors in regulation of arterial pressure during acute and chronic osmotic stress. Am J Physiol Regul Integr Comp Physiol. 2011;300:R460-R469.

     Not in our library10.1152/ajpregu.00371.2010

245. 245.

     Yang Z, Han D, Coote JH. Cardiac sympatho-exicatory action of PVN-spinal oxitocin neurones. Auton Neurosci. 2009;147:80-85.

     Not in our library10.1016/j.autneu.2009.01.013

246. 246.

     Yao Y, Fu LY, Zhang X, van den Pol AN. Vasopressin and oxytocin excite MCH neurons, but not other lateral hypothalamic GABA neurons. Am J Physiol Regul Integr Comp Physiol. 2012.

     Not in our library10.1152/ajpregu.00452.2011

Cited by papers we hold 3

• The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors · 2023
  No notice
• Oxytocin in the medial prefrontal cortex is involved in maternal care, maternal aggression and anxiolysis during the postpartum period · 2014
  Not checked
• Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.